Delivery Order SPE2DB20D3101-SPE2DB23FRXW9
- Not listed
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $13,877.40 for the supply of Eliquis 5 mg tablets. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of April 18, 2023. The contract is a Firm Fixed Price agreement with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $4,102.94 for the pharmaceutical product Eliquis 5 mg tablets. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of May 6, 2024. This award is not associated with a set-aside program. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $7,118.15 for the pharmaceutical product Eliquis 5 MG Tablet 60S. The award was made by the Defense Logistics Agency (DLA) on March 31, 2022, with an ultimate completion date of April 1, 2022. Amerisourcebergen is a major pharmaceutical distributor that holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $16,444.07 for the supply of Eliquis 5 mg tablets. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of January 25, 2023. The contract is a firm-fixed-price delivery order with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Delivery Order valued at $6,993.30 for the supply of Eliquis 5 mg tablets. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of June 5, 2023. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $8,163.70 for the pharmaceutical product Eliquis 2.5 mg tablets. The award was made by the Defense Logistics Agency (DLA), a defense agency, on March 7, 2023, with a completion date of March 8, 2023. The contract is a firm fixed-price delivery order with no set-aside designation, indicating open competition. Amerisourcebergen is a major pharmaceutical distributor that holds...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Eliquis 5 mg tablets. The $7,313.69 firm-fixed-price delivery order was issued by the Defense Logistics Agency (DLA) and has a completion date of September 13, 2023. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as the primary vehicle for the company to provide a comprehensive range of...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Eliquis 2.5 mg tablets. The $11,729.46 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) and has a completion date of March 31, 2022. Amerisourcebergen is an experienced pharmaceutical distributor that holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the company to...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $5,430.07 firm fixed-price delivery order is for the supply of Eliquis 2.5 mg tablets. The contract has an ultimate completion date of January 4, 2024. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that holds two significant Indefinite Delivery Contracts (IDCs) with the DLA and the Department of Justice Federal Bureau of Investigation,...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a $8,091.91 firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) for the pharmaceutical product Eliquis 5 mg tablet. The contract has an ultimate completion date of January 27, 2022 and does not have a set-aside designation, indicating open competition. Amerisourcebergen is a major pharmaceutical distributor that holds two significant Indefinite Delivery Contracts (IDCs) with the...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB23FRXW9Delivery Order
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $72,201.60 for the supply of Eliquis 2.5 mg tablets. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of September 19, 2023. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen is a major pharmaceutical distributor that holds significant Indefinite Delivery Contracts (IDCs) with the DLA Troop Support Medical and the Department of Justice Federal Bureau of Investigation, valued at up to $999,999,999.00 and $750,000.00 respectively. These IDCs enable the efficient procurement of a comprehensive range of pharmaceutical products and medical supplies to support military, veterans, and other federal healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $72.2k | 9/18/23 |